Home LiteratureArticle Details
PMID: 11404819 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer.

American journal of human genetics ·Vol. 69 ·No. 1 ·2001-07-00 ·Pages 138-47

Ritchie MD, Hahn LW, Roodi N, Bailey LR, Dupont WD, Parl FF, Moore JH

Abstract

One of the greatest challenges facing human geneticists is the identification and characterization of susceptibility genes for common complex multifactorial human diseases. This challenge is partly due to the limitations of parametric-statistical methods for detection of gene effects that are dependent solely or partially on interactions with other genes and with environmental exposures. We introduce multifactor-dimensionality reduction (MDR) as a method for reducing the dimensionality of multilocus information, to improve the identification of polymorphism combinations associated with disease risk. The MDR method is nonparametric (i.e., no hypothesis about the value of a statistical parameter is made), is model-free (i.e., it assumes no particular inheritance model), and is directly applicable to case-control and discordant-sib-pair studies. Using simulated case-control data, we demonstrate that MDR has reasonable power to identify interactions among two or more loci in relatively small samples. When it was applied to a sporadic breast cancer case-control data set, in the absence of any statistically significant independent main effects, MDR identified a statistically significant high-order interaction among four polymorphisms from three different estrogen-metabolism genes. To our knowledge, this is the first report of a four-locus interaction associated with a common complex multifactorial disease.

MeSH Terms
Alleles Aryl Hydrocarbon Hydroxylases Breast Neoplasms/enzymology,genetics,metabolism Case-Control Studies Chromosome Mapping/methods,statistics & numerical data Computer Simulation Cytochrome P-450 CYP1A1/genetics Cytochrome P-450 CYP1B1 Cytochrome P-450 Enzyme System/genetics Estrogens/metabolism Female Gene Frequency/genetics Genetic Predisposition to Disease/genetics Genotype Humans Matched-Pair Analysis Methyltransferases/genetics Mutation, Missense/genetics Polymorphism, Genetic/genetics Reproducibility of Results Sample Size Statistics, Nonparametric Whites/genetics
Chemicals
Estrogens Cytochrome P-450 Enzyme System Aryl Hydrocarbon Hydroxylases CYP1B1 protein, human Cytochrome P-450 CYP1A1 Cytochrome P-450 CYP1B1 Methyltransferases caffeate O-methyltransferase
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Ritchie M D
Program in Human Genetics, Department of Molecular Physiology and Biophysics, Vanderbilt University Medical School, Nashville, TN 37232, USA.
Hahn L W
Roodi N
Bailey L R
Dupont W D
Parl F F
Moore J H
References (34)
34 references, click to expand
  1. A complete enumeration and classification of two-locus disease models.
    Hum Hered. 2000 Nov-Dec;50(6):334-49 PMID: 10899752
  2. Gene deletion of glutathione S-transferase theta: correlation with induced genetic damage and potential role in endogenous mutagenesis.
    Cancer Epidemiol Biomarkers Prev. 1995 Apr-May;4(3):253-9 PMID: 7606200
  3. Estrogen and the risk of breast cancer.
    N Engl J Med. 2001 Jan 25;344(4):276-85 PMID: 11172156
  4. A combinatorial partitioning method to identify multilocus genotypic partitions that predict quantitative trait variation.
    Genome Res. 2001 Mar;11(3):458-70 PMID: 11230170
  5. Effect of obesity on conversion of plasma androstenedione to estrone in postmenopausal women with and without endometrial cancer.
    Am J Obstet Gynecol. 1978 Feb 15;130(4):448-55 PMID: 629289
  6. Sex hormone binding globulin and risk factors for breast cancer in a population of normal women who had never used exogenous sex hormones.
    Br J Cancer. 1987 Nov;56(5):661-6 PMID: 3426933
  7. Breast cancer epidemiology.
    Cancer Res. 1988 Oct 15;48(20):5615-23 PMID: 3048646
  8. Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion.
    Proc Natl Acad Sci U S A. 1988 Oct;85(19):7293-7 PMID: 3174634
  9. Influence of exogenous estrogens, proliferative breast disease, and other variables on breast cancer risk.
    Cancer. 1989 Mar 1;63(5):948-57 PMID: 2914301
  10. Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene.
    J Biochem. 1991 Sep;110(3):407-11 PMID: 1722803
  11. Breast cancer (1)
    N Engl J Med. 1992 Jul 30;327(5):319-28 PMID: 1620171
  12. The risk of determining risk with multivariable models.
    Ann Intern Med. 1993 Feb 1;118(3):201-10 PMID: 8417638
  13. Reproductive factors and breast cancer.
    Epidemiol Rev. 1993;15(1):36-47 PMID: 8405211
  14. Genetics of CYP1A1: coamplification of specific alleles by polymerase chain reaction and association with breast cancer.
    Cancer Epidemiol Biomarkers Prev. 1994 Sep;3(6):511-4 PMID: 8000303
  15. Cytochrome P4501A1 and glutathione S-transferase (M1) genetic polymorphisms and postmenopausal breast cancer risk.
    Cancer Res. 1995 Aug 15;55(16):3483-5 PMID: 7627950
  16. Prospective study of relative weight and risk of breast cancer: the Breast Cancer Detection Demonstration Project follow-up study, 1979 to 1987-1989.
    Am J Epidemiol. 1996 May 15;143(10):985-95 PMID: 8629617
  17. Reversal of relation between body mass and endogenous estrogen concentrations with menopausal status.
    J Natl Cancer Inst. 1996 Jun 5;88(11):756-8 PMID: 8637031
  18. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies.
    Lancet. 1996 Jun 22;347(9017):1713-27 PMID: 8656904
  19. Molecular mechanisms of estrogen carcinogenesis.
    Annu Rev Pharmacol Toxicol. 1996;36:203-32 PMID: 8725388
  20. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders.
    Pharmacogenetics. 1996 Jun;6(3):243-50 PMID: 8807664
  21. A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility.
    Cancer Res. 1996 Nov 1;56(21):4965-9 PMID: 8895751
  22. Who's afraid of epistasis?
    Nat Genet. 1996 Dec;14(4):371-3 PMID: 8944011
  23. A simulation study of the number of events per variable in logistic regression analysis.
    J Clin Epidemiol. 1996 Dec;49(12):1373-9 PMID: 8970487
  24. In vitro kinetics of two human CYP1A1 variant enzymes suggested to be associated with interindividual differences in cancer susceptibility.
    Biochem Biophys Res Commun. 1997 Feb 3;231(1):227-30 PMID: 9070254
  25. Genetic polymorphism of catechol-O-methyltransferase (COMT): correlation of genotype with individual variation of S-COMT activity and comparison of the allele frequencies in the normal population and parkinsonian patients in Finland.
    Pharmacogenetics. 1997 Feb;7(1):65-71 PMID: 9110364
  26. Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators.
    Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10937-42 PMID: 9380738
  27. An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer.
    Cancer Res. 1997 Dec 15;57(24):5493-7 PMID: 9407957
  28. Breast cancer and CYPIA1, GSTM1, and GSTT1 polymorphisms: evidence of a lack of association in Caucasians and African Americans.
    Cancer Res. 1998 Jan 1;58(1):65-70 PMID: 9426059
  29. Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1.
    Am J Hum Genet. 1998 Mar;62(3):573-84 PMID: 9497261
  30. Genetic polymorphisms in catechol-O-methyltransferase, menopausal status, and breast cancer risk.
    Cancer Res. 1998 May 15;58(10):2107-10 PMID: 9605753
  31. Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer.
    Cancer Res. 1998 Nov 15;58(22):5038-41 PMID: 9823305
  32. Catechol-O-methyltransferase and breast cancer risk.
    Carcinogenesis. 1998 Nov;19(11):1943-7 PMID: 9855007
  33. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer.
    Lancet. 1997 Oct 11;350(9084):1047-59 PMID: 10213546
  34. Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity.
    Cancer Res. 2000 Jul 1;60(13):3440-4 PMID: 10910054
Article Info
Journal
American journal of human genetics
Abbr.
Am J Hum Genet
ISSN
0002-9297
Published
2001-07-00
Epub
2001-00-11
Pages
138-47
Language
English
Region
United States
NLM ID
0370475
PMCID
PMC1226028
Subset
IM
Grants
NCI NIH HHS · T32 CA078136 · United States
NCI NIH HHS · R01 CA/ES 83752 · United States
NCI NIH HHS · T32 CA78136 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com